Review of atypical antipsychotics and weight gain

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 23, 2001, Pages 5-12

  Sussman, N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HOSPITAL PATIENT; HUMAN; INSTITUTIONALIZATION; LONG TERM CARE; OUTPATIENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; TREATMENT PLANNING; WEIGHT GAIN;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CLINICAL TRIALS; CLOZAPINE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HOSPITALIZATION; HUMANS; PIPERAZINES; PIRENZEPINE; RESEARCH DESIGN; SCHIZOPHRENIA; THIAZOLES; WEIGHT GAIN;

EID: 0034790798     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Antipsychotic-induced weight gain: A comprehensive research synthesis
2. Antipsychotic-induced weight gain: A review of the literature
3. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
4. Bodyweight gain with atypical antipsychotics: A comparative review
5. Annual deaths attributable to obesity in the United States
6. Physical and psychological consequences of weight gain
7. The clinical implications of weight gain in schizophrenia
8. The disease burden associated with overweight and obesity
9. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
10. Induction of obesity by psychotropic drugs
11. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
12. Genetic variants of the serotonin system and weight change during clozapine treatment
13. Weight gain with risperidone among patients with mental retardation: Effect of calorie restriction
14. Risperidone-associated weight gain in children and adolescents: A retrospective chart review
15. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior
16. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study)
17. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
18. Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients
19. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
20. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
21. Effective open-label treatment of tourette's disorder with olanzapine
22. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): A 12-week open trial
23. Mood stabilizer augmentation with olanzapine in acutely manic children
24. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia
25. Weight changes in patients treated with quetiapine
26. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control
27. Ziprasidone: Comprehensive overview and clinical use of a novel antipsychotic
28. Long-term efficacy of oral ziprasidone in schizophrenia: Results of three controlled trials
29. Improvement in indices of health status in schizophrenic outpatients following a switch to ziprasidone from conventional antipsychotics, olanzapine, and risperidone
30. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder
31. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
32. Weight gain over 4 months in schizophrenia patients: A comparison of olanzapine and risperidone
33. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine- and risperidone-treated inpatients
34. Comparative side effects of atypical neuroleptics in children and adolescents
35. Ziprasidone vs olanzapine in schizophrenia: Results of a double-blind trial
36. Insulin resistance in olanzapineand ziprasidone-treated patients: Interim results of a double-blind, controlled 6-week trial
37. Topiramate as add-on treatment for patients with bipolar mania
38. 2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients